Core Viewpoint - Enwei Pharmaceutical (301331.SZ) announced that its controlling shareholder, Chengdu Enwei Investment (Group) Co., Ltd., plans to transfer 4 million shares through a pricing inquiry, representing 3.89% of the company's total share capital and 3.93% of the total share capital after excluding repurchased shares. The reason for the transfer is due to the shareholder's funding needs. The transfer will not be conducted through centralized bidding or block trading, and the shares acquired through the inquiry transfer cannot be transferred by the acquirer within six months [1]. Group 1 - The controlling shareholder plans to transfer 4 million shares [1] - The shares represent 3.89% of the total share capital [1] - The transfer is motivated by the shareholder's funding needs [1] Group 2 - The transfer will not occur through centralized bidding or block trading [1] - Acquired shares cannot be transferred within six months [1]
恩威医药：控股股东拟询价转让400万股股份